Diabetes

The FDA has granted priority review to Roche's injectable ranibizumab (Lucentis) treatment for diabetic retinopathy.

A practical approach to daily life with the support of a pharmacist can make a difference.

Patients with diabetes may not know about OTC products formulated to meet their specific needs.

The FDA has approved the intravitreal implant, Iluvien 0.19 mg, as the first long-term treatment for diabetic macular edema.

The dexamethasone intravitreal implant, Ozurdex, is now indicated to treat all patients with diabetic macular edema.

Pharmacists who participate in community-based diabetes care teams play a pivotal role in reducing A1C levels among patients with poorly controlled diabetes.

A recent metaanalysis suggests that prediabetes increases the risk of developing certain cancers, particularly in tissues located near the gastrointestinal tract.

The FDA has cleared the Nova StatStrip Glucose Hospital Meter System to become the first blood glucose monitoring system for use in critically ill patients who have been hospitalized.

Combined with bolus insulin aspart (NovoLog), insulin degludec (Tresiba) improves long-term glycemic control in children and adolescents with type 1 diabetes.

The FDA today approved dulaglutide (Trulicity), a once-weekly injectable therapy indicated to improve blood sugar control in adults with type 2 diabetes.

Results show pharmacists and other healthcare providers can work together to successfully empower patients disproportionately affected by diabetes to achieve improved clinical outcomes.

The risk for developing prediabetes was doubled among hypertensive patients who drank more than 3 cups of coffee per day.

Extended-release naltrexone hydrochloride and bupropion hydrochloride (Contrave) has been approved as an adjunct therapy for chronic weight management in obese adults.

The prevalence of type 2 diabetes mellitus (T2DM) in the United States has been rising for decades. A new study suggests that body mass index is the largest contributor to the rising rate of T2DM.

AstraZeneca's injectable medication to improve glycemic control among adults with type 2 diabetes is now widely available across US pharmacies.

Learn the fascinating details of the discovery of incretin-active agents, including DPP4 inhibitors, GLP-1 agonists, and GLP-2 agonists.

New blood glucose monitoring system transfers data to iOS devices using the headphone jack, rather than an adaptor or other technology.

The NephroCheck test detects levels of 2 AKI markers, which can determine whether the condition will progress to moderate or severe injury.

A model used in 3 studies was found to accurately predict serious complications in patients with type 1 diabetes.

Children and adolescents who received antipsychotic medications had an increased absolute risk of developing type 2 diabetes.